Skip to main content
BCRX logo

BCRX · Biocryst Pharmaceuticals Inc · Executive Compensation

Track BCRX — free
$7.32 +0.02 (+0.27%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.88B
Shares
257.30M
Volume · Nov 19 3.78M Avg daily vol (3M) 4.93M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Jon P. Stonehouse $12,951,082
Charles Gayer $9,627,868
Babar Ghias $6,748,152
Alane P. Barnes $5,616,032
Helen Thackray $4,339,624
Anthony Doyle $2,141,135
Fiscal 2024
Executive Total
Jon P. Stonehouse $8,317,286
Helen Thackray $3,568,850
Charles Gayer $3,375,210
Anthony Doyle $3,287,271
Alane P. Barnes $3,241,696
Fiscal 2023
Executive Total
Jon P. Stonehouse $4,777,778
Helen Thackray $2,393,933
Alane P. Barnes $1,932,072
Anthony Doyle $1,790,349
Charles Gayer $1,738,544
Fiscal 2022
Executive Total
Jon P. Stonehouse $6,982,994
Helen Thackray $3,497,932
William P. Sheridan $2,658,421
Yarlagadda S. Babu $2,565,782
Anthony Doyle $2,281,851
Alane P. Barnes $2,210,762
Charles Gayer $2,198,862
Fiscal 2021
Executive Total
Megan Sniecinski $7,929,124
Jon P. Stonehouse $7,061,225
Helen Thackray $6,881,396
Anthony Doyle $2,890,803
William P. Sheridan $2,531,231
Yarlagadda S. Babu $2,386,139
Fiscal 2020
Executive Total
Jon P. Stonehouse $6,034,941
Anthony Doyle $4,117,930
William P. Sheridan $2,679,920
Yarlagadda S. Babu $2,264,785
Megan Sniecinski $2,012,335
Thomas R. Staab II $692,790
Fiscal 2019
Executive Total
Jon P. Stonehouse $2,284,297
Megan Sniecinski $2,176,954
Yarlagadda S. Babu $1,083,307
William P. Sheridan $1,067,183
Thomas R. Staab II $910,354
Fiscal 2018
Executive Total
Jon P. Stonehouse $4,167,643
William P. Sheridan $2,349,219
Thomas R. Staab II $1,797,270
Yarlagadda S. Babu $1,755,510
Fiscal 2017
Executive Total
Jon P. Stonehouse $3,921,189
William P. Sheridan $1,808,550
Thomas R. Staab II $1,723,588
Drug Discovery $1,639,444

Executive changes

Person Change Filed
Amy E. McKee, M.D. Appointed 2026-06-12
Jon P. Stonehouse Appointed 2026-06-12
Theresa M. Heggie Already on the board
Since at least 2018: re-election or new board role
2026-06-12
Jill C. Milne Appointed 2025-10-14
Dr. Helen Thackray
“Dr. Thackray cited no disagreement with the Board of Directors (the “Board”) or management relating to the Company, its operations, policies, or practices.”
Resigned 2025-08-11
Charlie Gayer Appointed 2025-07-31
Charlie Gayer Appointed 2025-07-31
Charlie Gayer Appointed 2025-07-31
Jon Stonehouse
“Mr. Stonehouse cited no disagreement with the Board or management relating to the Company, its operations, policies, or practices, and he will continue to serve as a member of the Board following his retirement.”
Retired 2025-07-31
Babar Ghias Appointed 2025-07-07
Babar Ghias Appointed 2025-07-07
George B. Abercrombie
“Mr. Abercrombie cited no disagreement with the Board or management relating to the Company, its operations, policies, or practices.”
Retired 2025-06-16
Steven Frank Appointed 2025-05-01
Jon P. Stonehouse Appointed 2025-04-10
Jon P. Stonehouse Appointed 2025-04-10
Anthony Doyle Resigned 2025-04-10
Anthony Doyle Resigned 2025-04-10
Anthony Doyle
“Mr. Doyle’s resignation from the Company is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.”
Resigned 2025-03-04
A. Machelle Sanders Already on the board
Since at least 2022: re-election or new board role
2024-06-13
Vincent J. Milano Already on the board
Since at least 2021: re-election or new board role
2024-06-13
Nancy J. Hutson Already on the board
Since at least 2012: re-election or new board role
2024-06-13
Kenneth B. Lee, Jr.
“Mr. Lee cited no disagreement with the Board or management relating to the Company, its operations, policies, or practices.”
Retired 2023-12-01
Michael L. Jones
“His resignation is not due to any disagreement on any matter relating to the Company’s operations, policies, or practices.”
Resigned 2023-07-11
Jon P. Stonehouse Appointed 2023-06-14
Amy E. McKee, M.D. Appointed 2023-06-14

Leadership

Key facts CIK 882796 CUSIP 09058V103 13F (30d) 344 filings 320 filers Visit website Investor relations